EXACT Therapeutics announces appointment of Caspar Foghsgaard as SVP Commercial & Business Development

27 Sep 2023 14:55 CEST

OSLO, 27 September 2023: EXACT THERAPEUTICS AS (“EXACT-Tx”, Euronext Growth:
EXTX), a clinical stage precision health company utilising Acoustic Cluster
Therapy (ACT®) across multiple therapeutic areas, is delighted to announce that
Caspar Foghsgaard is joining the company as Senior Vice President Commercial and
Business Development, effective 1 November 2023.

“We are thrilled to welcome Caspar to our leadership team as our Senior Vice
President of Commercial and Business Development. Caspar’s extensive experience
and dynamic approach will be instrumental in driving the future growth of
EXACT-Tx. With the recent announcement of the positive initial clinical results
from our ACTIVATE trial, we are entering an exciting phase, during which we will
shape the future of the Company”, says Per Walday, CEO of EXACT-Tx.

Caspar Foghsgaard joins Exact Therapeutics from Nykode Therapeutics where his
latest role was as Sr. Director Special Projects and part of the extended
leadership team. He joined Nykode in 2018 and have been closely involved in
Nykode’s transformation from a small biotech to a leading company at Oslo Stock
Exchange. Prior to his role as Sr. Director Special Projects, he was heading
Nykode’s business development activities as Director Business Development. Other
previous employers include Arcus where he was responsible for business
development in the spirits division and part of the divisional management, and
Elopak as Program Director Strategy. In addition, he has held various business
development and strategy positions including with Novozymes in Denmark, U.S. and
U.K.


For more information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement – Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement – with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com

About ACT®
• ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
• ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
• Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (CNS, immunotherapy) and product classes.

Forward looking statements: This announcement and any materials distributed in
connection with this announcement may contain certain forward-looking
statements. By their nature, forward-looking statements involve risk and
uncertainty because they reflect the Company's current expectations and
assumptions as to future events and circumstances that may not prove accurate. A
number of material factors could cause actual results and developments to differ
materially from those expressed or implied by this forward-looking statement.

More information:
Access the news on Oslo Bors NewsWeb site